Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00082589 · ClinicalTrials.gov registry record · Phase 4

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

A Phase 4 study of Heart Failure, Congestive, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
250
Enrollment target
20
Study locations

NCT00082589 is a Phase 4 study of Heart Failure, Congestive that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 250 participants, below the 634-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00082589, a Phase 4 study of Heart Failure, Congestive, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

Conditions Studied

Heart Failure, Congestive

Interventions

  • DRUG Eplerenone

Study Locations (20)

California

  • Pfizer Investigational Site - Castro Valley
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - Santa Rosa
  • Pfizer Investigational Site - Walnut Creek

Florida

  • Pfizer Investigational Site - Fort Lauderdale
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville

Georgia

  • Pfizer Investigational Site - Atlanta
  • Pfizer Investigational Site - Augusta
  • Pfizer Investigational Site - Covington

Illinois

  • Pfizer Investigational Site - Bloomington
  • Pfizer Investigational Site - Normal

Indiana

  • Pfizer Investigational Site - Indianapolis
  • Pfizer Investigational Site - Indianapolis

Michigan

  • Pfizer Investigational Site - Ann Arbor
  • Pfizer Investigational Site - Detroit

Colorado

  • Pfizer Investigational Site - Denver

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2004-04
Est. Completion 2006-03
Phase Phase 4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00082589

The ClinicalTrials.gov registry entry for NCT00082589 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 634-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (61% lower). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.

NCT00082589 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00082589 about?

NCT00082589 is a clinical study titled "The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure". The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

What is the current status of trial NCT00082589?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2004-04. Estimated completion is 2006-03.

What conditions does trial NCT00082589 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00082589?

The interventions under investigation include: Eplerenone (DRUG).

Who is sponsoring clinical trial NCT00082589?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00082589 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure, Congestive

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.